Regenetech Achieves a 60-Fold Increase of Adult Stem Cells Through Its cellXpansion(TM) Process
Posted on: Tuesday, 16 October 2007, 09:01 CDT
Regenetech, Inc., the adult stem cell company which has built upon NASA licensed technology, announced that the Company has significantly augmented its cell multiplication capabilities for CD34+38- peripheral blood progenitor cells (adult stem cells). These new results were achieved through the continued development of cell culture conditions for Regenetech's proprietary and patented Intrifuge™ cellXpansion™ technology. Developing a significant and reliable technology for adult stem cell growth and multiplication currently represents one of the most significant barriers preventing more widespread autologous adult stem cell therapeutic use.
Under the new, improved growth conditions, the number of adult stem cells increased by 50-200 times the original number, an achievement accomplished in as few as 6 days. Compared to other serum-free media, the optimized Regenetech formulation yields considerably higher cell numbers than were previously achievable, significantly enhancing the market competitiveness and commercial potential of the cellXpansion™ technology.
David Bonner, CEO of Regenetech, said: "We are delighted with the progress that the team has made. This is a significant step forward for our technology, and we are excited about what it will allow us to do in the future in terms of providing doses of adult stem cells to help patients. This development will demonstrate to the wider industry that adult stem cells can be expanded in three-dimensional conditions to achieve therapeutic doses for autologous use. We believe this technology will have a significant impact on many treatments and will bring us even closer to realizing the potential for treating diseases through the use of expanded adult stem cells."
Regenetech's technology uses NASA based technologies which were discovered in space experiments in which adult stem cells and tissue are grown in a weightless three-dimensional environment. The stem cells are harvested from the patient's own blood and multiplied in Regenetech's IntrifugeTM Bioreactor in order to achieve therapeutic quantities for re-introduction into the original patient. The technology is capable of producing therapeutic quantities of adult stem cells rapidly and at reasonable cost. Regenetech is licensing the technology broadly to ensure the technology is available for general use by researchers and commercial operators.
For more information about Regenetech, contact twang@regenetech.com or visit www.regenetech.com. For licensing opportunities, contact rclark@regenetech.com.
Forward Looking Statements: The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements.
Source: Business Wire
Related Articles
- Research Provides Documentation That Tumor 'Stem-Like Cells' Exist In Benign Tumors
- Using a Single Virus to Convert Adult Cells to Embryonic Stem Cells
- Technique for Rapidly Reprogramming Adult Cells Into Stem Cells Published in PLoS Biology
- StemCells Wins NIH Grant to Develop Cell-Based Therapeutic for Hepatitis
- StemCells, Inc. Receives NIH Grant to Pursue Cell-Based Therapeutic for Hepatitis C
- Anti-HIV NanoViricide Drug Candidate Demonstrates Significant Therapeutic Efficacy in Animal Trials
- Journal of Neuroimmunology Publishes Study Results Showing That Geron's Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack By the Human Immune System
- Research Indicates Geron's Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack By the Human Immune System
- Cytori Therapeutics Authors Review on Opportunity for Adipose Stem & Regenerative Cells in Cosmetic and Reconstructive Surgery
- Adult cells in mice shown to mimic embryonic stem cells
 |
 |
User Comments (0)
RSS Feeds